113 results
10-K
2023 FY
EX-10.6
INTI
Inhibitor Therapeutics, Inc.
Annual report
29 Mar 24
4:05pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
18 Oct 23
Departure of Directors or Certain Officers
9:54am
8-K
EX-10.2
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.4
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.3
xmh6ypq7
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
nvhb954i
18 Jan 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
oxcau
17 Dec 20
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
cvrtpr
6 May 20
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-10.1
527js egwqj4k
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.2
rotjavti6n5z
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.2
85webeog4g1
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am
8-K
EX-10.1
3gd v6flm2bi5
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am